Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T
On February 23, 2026, Gilead agreed to acquire Arcellx in
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
On February 9, Eli Lilly agreed to buy Orna Therapeutics
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
On a cold Tuesday in early January, Amgen quietly made
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle
Layoffs Hit Biotech Hubs Hard In labs from Boston’s Kendall
MOST POPULAR
